PHXM - PHAXIAM Therapeutics S.A.

3.02
3.020   100.000%

Share volume: 0
Last Updated: 03-08-2024

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Historical prices Events Documents Notes Dividends
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
-32.61%
2 Year
638.10%
Key data
Stock price
$3.02
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.91 - $5.29
52 WEEK CHANGE
-$35.42
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
60.751 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Thibaut du Fayet
Region: US
Website: phaxiam.com/en/
Employees: 49
IPO year: 2016
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry:
Sector:

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Recent news